Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44)

The summary for the Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44): The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the SBIR program. SBIR Phase I projects under this FOA supportpreliminary steps in the process for lead optimization or preclinical development of therapeutics. SBIR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a SBIR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.

Federal Grant Title:	Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-17-130
Type of Funding:	Grant
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 5th, 2020
Original Application Deadline:	January 5th, 2020
Posted Date:	January 24th, 2017
Creation Date:	January 24th, 2017
Archive Date:	February 5th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 24th, 2017

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-17-130.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) ...; • Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Compl...; • Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed); • Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney ...; • Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices ...; • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...; • Immune Tolerance Network (UM1 Clinical Trial Required); • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...; • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...